What is tesamorelin?
The US EGRIFTA WR label describes tesamorelin as a synthetically produced analogue of human growth hormone-releasing factor. That identifies a releasing-factor analogue rather than supplying a clinical finding for the Tesamorelin 10MG vial. The supplier name and amount are separate presentation details. EGRIFTA WR prescribing information.
The label states that EGRIFTA WR stimulates growth-hormone production and increases serum IGF-1. These are named activities in the medicine's label. They do not independently establish benefit, matching formulation or performance for a supplier vial. EGRIFTA WR prescribing information.
Tesamorelin, abdominal fat and weight loss
EGRIFTA WR is indicated in the United States to reduce excess abdominal fat in HIV-infected adults with lipodystrophy. EGRIFTA WR prescribing information.
The label explicitly states that the medicine is not indicated for weight-loss management and describes it as weight neutral. The restricted abdominal-fat indication and weight-neutral limitation belong together; they do not support a general weight-loss claim for tesamorelin or for this 10MG vial. EGRIFTA WR prescribing information.
EGRIFTA WR glucose and diabetes warning
The EGRIFTA WR label warns that glucose intolerance or diabetes may develop. This is a concrete safety detail alongside the label's GH-production and IGF-1 statements, rather than a reason to summarize those activities as an unqualified metabolic benefit. EGRIFTA WR prescribing information.
Both the indication and warning concern the named US medicine. They do not authenticate the supplier vial or make its listed 10MG a concentration or use instruction. The tesamorelin guide offers the wider topic context, and the 10mg pen is a separately documented presentation. EGRIFTA WR prescribing information.
Tesamorelin weight-loss questions
Does reducing excess abdominal fat mean weight-loss management?
The EGRIFTA WR label distinguishes them: it has the specified HIV-lipodystrophy abdominal-fat indication, describes a weight-neutral effect and excludes weight-loss management. EGRIFTA WR prescribing information.
